SUMMARY Cyclosporin A pharmacokinetics were studied after oral (4-14 mg/kg body weight) and intravenous dosing (1-5-3-5 mg/kg) in 13 orthotopic liver transplant recipients before and after permanent clamping of the biliary T-tube. After T-tube clamping, cyclosporin A absorption was faster and more complete with the mean time of peak concentration, tmax, reduced to around three hours from around six hours and mean bioavailability rising from only 16 6% (n=13) to 30°% in the entire group (n=11 after clamping) or to 35% after excluding two patients who developed severe cholestasis after the preclamping study. Bioavailability in these two patients fell below 8% and to around 1% in a further patient with severe graft dysfunction. Clamping reduced the metabolic clearance of cyclosporin A by only 25% from a mean before clamping of 2 9 mVmin/kg to 2 3 ml/min/ kg (n=11). Oral cyclosporin A becomes a reliable means of maintaining therapeutic drug concentrations only after bioavailability increases in association with T-tube clamping and in the absence of severe liver dysfunction or cholestasis.
Pharmacokinetic studies have shown that the absorption of cyclosporin A is low, highly variable and influenced by various factors, particularly age, gastric emptying and hepatic and intestinal dysfunction.'-' In liver transplant recipients, there is also evidence that changes in bile flow, associated with insertion, opening and clamping of the biliary T-tube, may affect cyclosporin A absorption. Thus, Andrews et al4 reported changes in trough cyclosporin A concentrations in three patients and Venkataramanan et al' showed a higher profile of blood concentrations after oral cyclosporin A dosing in a single patient after Ttube clamping. While additional studies in dogs showed that diversion of bile flow from the intestine reduced cyclosporin A blood concentrations5 the that decreased drug clearance cannot be excluded as an alternative to increased absorption.
The present study was carried out to document the influence of biliary T-tube clamping in liver transplant recipients on the pharmacokinetic profiles of cyclosporin A administered both orally and intravenously. Particular emphasis was placed on recording changes in the bioavailability and clearance of the drug such that its absorption could be assessed in relation to the appropriate time for commencement of oral therapy.
Methods

PA I I NITS
Informed consent was obtained from 13 Figure 1 shows the profile of cyclosporin A blood concentrations after intravenous and oral administration both before and after T-tube clamping (one week apart) in a representative patient (OL 313). Whilst the T-tube was draining freely, cyclosporin A blood concentrations increased only slightly after oral dosing ( Fig. 1 : unclamped) and the low area under the blood cyclosporin A concentration versus time curve (AUC) was reflected in a low level of bioavailability (14.5%). With clamping and restoration of the entire bile flow to the intestine there was a rapid rise in cyclosporin A blood concentrations after oral dosing ( Fig. 1: clamped) and AUC increased nearly 3-fold (3007 versus 1164 nmol.h/l per 100 mg drug) while bioavailability rose to 32%. Table 2 summarises the results obtained in the 13 patients, 11 of whom were studied both before and after T-tube clamping. Mean bioavailability (n= Il) increased substantially from 18-8 (11-0)% before to 29'9 (15 -9)% (0O >p>0-05) after clamping of the Ttube. Bioavailability was highest (56%) in the patient (OL 314) studied at the longest interval after transplantation (162/3 days) but this was only marginally greater than the value of 53% found at 25/26 days in case OL 308. Bioavailability was lowest (-1%) in patient OL 283 in whom hepatic artery thrombosis was diagnosed immediately after the investigations were completed and the minimal absorption of cyclosporin A in this patient is shown in Figure 2 . The dose normalised AUC after oral cyclosporin A was higher after clamping in all but two cases (OL 307 and 311). In these patients, AUC was high before clamping because of a pronounced late absorption peak but it was substantially reduced after clamping (by around 80%) and there were corresponding marked decreases in cyclosporin A bioavailability (from 29 and 44% to 8 and 5%, respectively). These two subjects differed from the remainder in that their graft function was deteriorating at the time of the second study (Table 1) with severe cholestasis (serum bilirubin 390 and 593 [tmol/l) caused by chronic rejection. The reduction in cyclosporin A bioavailability seen in association with the deteriorating liver function is shown in Figure 3 for one of these patients (OL 311). On the basis of this dysfunction, "' they will overestimate drug ients were excluded from the analysis and in concentrations because of crossreactivity of the iinder both the mean bioavailability and the polyclonal antibody with metabolites of cyclosporin rmalised AUC after oral dosing showed A."' This could lead to an overestimation of bioit increases (p<0.01) after T-tube clamping availability, particularly before clamping when 1)% to 35 1 (12.0)% and 1464 (747) to 3733 cyclosporin A values by radioimmunoassay are nol.h/l), respectively; n=9).
especially high due to liver dysfunction," and to an ate of cyclosporin A absorption was also underestimation of metabolic clearance after clampter T-tube clamping with the time of mean ing because of an increased biliary recirculation of blood concentrations after oral dosing cyclosporin A metabolites. Therefore, it is of note from 6-1 to 3 3 hours (n=11). In nine that the same 25% decrease in clearance and a 2.7-11 patients mean dose normalised AUC fold increase in bioavailability were noted after ravenous dosing rose following clamping clamping when cyclosporin A was assayed by high 0.05). The metabolic clearance of performance liquid chromatography (unpublished rin A (dose/iv AUC) ranged from 1 18 to observations). While increased cyclosporin A nin/kg before clamping and from 1 23 to 322 absorption underlies the increase in the biog afterwards. Values in the two patients who availability of the drug after T-tube clamping, the .d severe cholestasis were low both before decreased clearance is less obviously explained. As d 2 06 ml/min/kg) and after clamping (1-83 already discussed, reductions in the renal excretion ; ml/min/kg) and changed in parallel with or extrahepatic metabolism of cyclosporin A or ilirubin levels. When these two cases were increases in its enterohepatic recirculation seem from the analysis mean clearance fell unlikely and there was no evidence for a deterioraitly after clamping (p=005). '4 and that trough blood levels4 and the relative bioavailability of the drug (derived without intravenous data') rose after biliary T-tube clamping. The major clinical implication of our present findings is that the administration of conventional oral preparations of cyclosporin A can provide neither reliable nor economic therapy until the biliary T-tube is clamped. In the presence of severe liver dysfunction and cholestasis, it is essential to use intravenous cyclosporin A if therapeutic drug concentrations are to be maintained.
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